Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms

Clinical Cancer Research

Volumn 16, Issue 2, 2010, Pages 497-508

  Culp, Patricia A ^a   Choi, Donghee ^a   Zhang, Yongke ^a   Yin, Johnny ^a   Seto, Pui ^a   Ybarra, Suzanne E ^a   Su, Mian ^a   Sho, Mien ^a   Steinle, Roxanne ^b   Wong, Melanie H L ^a   Evangelista, Ferdinand ^a   Grove, Jennifer ^a   Cardenas, Marie ^a   James, Marjorie ^a   Hsi, Eric D ^b   Chao, Debra T ^a   Powers, David B ^a   Ramakrishnan, Vanitha ^a   Dubridge, Robert ^a  

^a Facet Biotech   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [7 ADAMANTYL 6 [(2 METHOXYETHOXY)METHOXY] 2 NAPHTHYL]BENZOIC ACID; COMPLEMENTARY DNA; GENE PRODUCT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DNA MICROARRAY; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; TWEAKR GENE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASMS; NIH 3T3 CELLS; SIGNAL TRANSDUCTION; TUMOR BURDEN; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 74549220324     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1929     Document Type: Article

References (50)

1. Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003;14:193-209.
2. Bradley JR, Pober JS. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 2001;20:6482-91.
3. Tamada K, Chen L. Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules. Cancer Immunol Immunother 2006;55:355-62.
4. Younes A, Kadin ME. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 2003;21:3526-34.
5. Segal B, Rhodus NL, Patel K. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106:778-87.
6. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008;7:411-25.
7. Lynch CN, Wang YC, Lund JK, et al. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999;274:8455-9.
8. Campbell S, Burkly LC, Gao HX, et al. Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J Immunol 2006;176:1889-98.
9. Campbell S, Michaelson J, Burkly L, Putterman C. The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity. Front Biosci 2004;9:2273-84.
10. Zhao Z, Burkly LC, Campbell S, et al. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 2007;179:7949-58.
11. Dogra C, Hall SL, Wedhas N, Linkhart TA, Kumar A. Fibroblast growth factor inducible 14 (Fn14) is required for the expression of myogenic regulatory factors and differentiation of myoblasts into myotubes. Evidence for TWEAK-independent functions of Fn14 during myogenesis. J Biol Chem 2007;282:15000-10.
12. Michaelson JS, Cho S, Browning B, et al. Tweak induces mammary epithelial branching morphogenesis. Oncogene 2005;24:2613-24.
13. Polek TC, Talpaz M, Darnay BG, Spivak-Kroizman T. TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. J Biol Chem 2003;278:32317-23.
14. Chicheportiche Y, Bourdon PR, Xu H, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997;272:32401-10.
15. Kawakita T, Shiraki K, Yamanaka Y, et al. Functional expression of TWEAK in human colonic adenocarcinoma cells. Int J Oncol 2005;26:87-93.
16. Nakayama M, Ishidoh K, Kayagaki N, et al. Multiple pathways of TWEAK-induced cell death. J Immunol 2002;168:734-43.
17. Feng SL, Guo Y, Factor VM, et al. The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol 2000;156:1253-61.
18. Han H, Bearss DJ, Browne LW, et al. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002;62:2890-6.
19. Wang S, Zhan M, Yin J, et al. Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene 2006;25:3346-56.
20. Tran NL, McDonough WS, Donohue PJ, et al. The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol 2003;162:1313-21.
21. Willis AL, Tran NL, Chatigny JM, et al. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res 2008;6:725-34.
22. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A 1989;86:10029-33.
23. Levitt M. Molecular dynamics of native protein. I. Computer simulation of trajectories. J Mol Biol 1983;168:595-617.
24. Drobyski WR, Gottlieb M, Carrigan D, et al. Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients. Transplantation 1991;51:1190-6.
25. Henshall SM, Afar DE, Hiller J, et al. Survival analysis of genomewide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 2003;63:4196-203.
26. Strome SE, Sausville EA, Mann D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 2007;12:1084-95.
27. Kipps TJ, Parham P, Punt J, Herzenberg LA. Importance of immuno-globulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J Exp Med 1985;161:1-17.
28. Steplewski Z, Sun LK, Shearman CW, et al. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci U S A 1988;85:4852-6.
29. Lubeck MD, Steplewski Z, Baglia F, et al. The interaction of murine IgG subclass proteins with human monocyte Fc receptors. J Immunol 1985;135:1299-304.
30. Wiley SR, Cassiano L, Lofton T, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001;15:837-46.
31. Brown SA, Hanscom HN, Vu H, Brew SA, Winkles JA. TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules. Biochem J 2006;397:297-304.
32. Kim K, Fisher MJ, Xu SQ, el-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000;6:335-46.
33. Bin L, Thorburn J, Thomas LR, et al. Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding. J Biol Chem 2007;282:28189-94.
34. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-30.
35. Wagner KW, Punnoose EA, Januario T, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007;13:1070-7.
36. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002;99:754-8.
37. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7.
38. Spiridon CI, Guinn S, Vitetta ES. A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies. Clin Cancer Res 2004;10:3542-51.
39. Fan Z, Masui H, Altas I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1993;53:4322-8.
40. Wang Y, Hailey J, Williams D, et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 2005;4:1214-21.
41. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001;38:17-23.
42. Kurai J, Chikumi H, Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007;13:1552-61.
43. Lopez-Albaitero A, Ferris RL. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 2007;133:1277-81.
44. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12.
45. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
46. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27:1122-9.
47. Carter P, Presta L, Gorman CM, et al. Humanization of an antip-185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285-9.
48. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6.
49. Gennari R, Menard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004;10:5650-5.
50. Varchetta S, Gibelli N, Oliviero B, et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 2007;67:11991-9.